Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 2917-2923

  Ghosn, Corine R ^a   Li, Yong ^a   Orilla, Werhner C ^a   Lin, Ton ^a   Wheeler, Larry ^a   Burke, James A ^a   Robinson, Michael R ^a   Whitcup, Scott M ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DEXAMETHASONE; H37RA ANTIGEN; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CILIARY BODY; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLAMMATORY CELL; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; IRIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SHAM PROCEDURE; VITREOUS BODY;

ANIMALS; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; CILIARY BODY; CYTOKINES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; GLUCOCORTICOIDS; IRIS; MYCOBACTERIUM TUBERCULOSIS; RABBITS; TREATMENT OUTCOME; TUBERCULOSIS, OCULAR; UVEITIS, ANTERIOR; UVEITIS, INTERMEDIATE; VITREOUS BODY;

EID: 79955960173     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5939     Document Type: Article

References (44)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516.
2. Munoz-Fernandez S, Martin-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006;20:487-505.
3. Rothova A, van Veenedaal WG, Linssen A, Glasius E, Kijlstra A, de Jong PT. Clinical features of acute anterior uveitis. Am J Ophthalmol. 1987;103:137-145.
4. Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis. Semin Ophthalmol. 2005;20:147-154.
5. Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. 3rd ed. Philadelphia: Mosby; 2004.
6. Hyndiuk RA. Radioactive depot-corticosteroid penetration into monkey ocular tissue, II: subconjunctival administration. Arch Ophthalmol. 1969;82:259-263.
7. Velez G, Whitcup SM. New developments in sustained release drug delivery for the treatment of intraocular disease. Br J Ophthalmol. 1999;83:1225-1229.
8. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36:442-453.
9. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467-471.
10. International Organization for Standardization. Biological Evaluation of Medical Devices, Part 6: Tests for Local Effects after Implantation. Geneva, Switzerland: International Organization for Standardization; 2007.
11. HumanMAP Version 1.6, Antigens. Rules-Based Medicine. http://www.rulesbasedmedicine.com/products-services/humanmap-services/. Accessed January 19, 2010.
12. Broekhuyse RM, Kuhlmann ED, Winkens HJ, Van Vugt AH. Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis, 1: induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium. Exp Eye Res. 1991;52:465-474.
13. Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU), 2: dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res. 1992;55:401-411.
14. Broekhuyse RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU), 3: induction by immunization with purified uveal and skin melanins. Exp Eye Res. 1993;56:575-583.
15. Smith JR, Rosenbaum JT, Williams KA. Experimental melanininduced uveitis: experimental model of human acute anterior uveitis. Ophthalmic Res. 2008;40:136-140.
16. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243:1186-1189.
17. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259-266.
18. Bolliger GA, Kupferman A, Leibowitz HM. Quantitation of anterior chamber inflammation and its response to therapy. Arch Ophthalmol. 1980;98:1110-1114.
19. Kulkarni PS, Bhattacherjee P, Eakins KE, Srinivasan BD. Anti-inflammatory effects of betamethasone phosphate, dexamethasone phosphate and indomethacin on rabbit ocular inflammation induced by bovine serum albumin. Curr Eye Res. 1981;1:43-47.
20. Williams RN, Paterson CA, Eakins KE, Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res. 1982;2:465-470.
21. Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004;20:533-547.
22. Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708-713.
23. Leopold IH, Gaster RV. Ocular inflammation and anti-inflammatory drugs. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea. New York: Churchill Livingstone; 1987:70.
24. Chang Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-86.
25. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.
26. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048-1054.
27. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10:133-139.
28. Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry. 2001;45:27-36.
29. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Methods. 2002;260:207-218.
30. Verma MJ, Lloyd A, Rager H, et al. Chemokines in acute anterior uveitis. Curr Eye Res. 1997;16:1202-1208.
31. Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci. 2005;46:4251-4259.
32. Ooi KG, Galatowicz G, Towler HM, Lightman SL, Calder VL. Multiplex cytokine detection versus ELISA for aqueous humor: IL-5, IL-10, and IFN-_ profiles in uveitis. Invest Ophthalmol Vis Sci. 2006;47:272-277.
33. Takase H, Futagami Y, Yoshida T, et al. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci. 2006;47:1557-1561.
34. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006;142: 192-194.
35. El-Shabrawi YG, Christen WG, Foster SC. Correlation of metalloproteinase- 2 and -9 with proinflammatory cytokines interleukin- 1b, interleukin-12 and the interleukin-1 receptor antagonist in patients with chronic uveitis. Curr Eye Res. 2000;20:211-214.
36. Klok AM, Luyendijk L, Zaal MJ, Rothova A, Hack CE, Kijlstra A. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol. 1998;82:871-874.
37. Ogard C, Sorensen TL, Krogh E. Increased CD40 ligand in patients with acute anterior uveitis. Acta Ophthalmol Scand. 2005;83:370-373.
38. Paroli MP, Teodori C, D'Alessandro M, Mariani P, Iannucci G, Paroli M. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur J Ophthalmol. 2007;17:938-942.
39. Braun A, Lommatzsch M, Neuhaus-Steinmetz U, et al. Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation. Br J Pharmacol. 2004; 141:431-440.
40. Cai D, Holm JM, Duignan IJ, et al. BDNF-mediated enhancement of inflammation and injury in the aging heart. Physiol Genomics. 2006;24:191-197.
41. Lorgis L, Amoureux S, Vergely C, Zeller M, Cottin Y, Rochette L. [Brain-derived neurotrophic factor (BDNF): role of this neurotrophin in cardiovascular physiopathology]. Ann Cardiol Angeiol (Paris). 2009;58:99-103.
42. Yang CH, Fang IM, Lin CP, Yang CM, Chen MS. Effects of the NF-_B inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. Invest Ophthalmol Vis Sci. 2005;46: 1339-1347.
43. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol. 2008;146:813-818.
44. Lowder C, Belfort R Jr, Lightman S, et al for the Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; doi:10.1001/archophthalmol.2010.339.